ADIA and GIC Lead $300 Million Investment Round in Taibang Biologic Group
Posted on 08/02/2022
China’s Taibang Biologic Group, a plasma products maker, raised US$ 300 million co-led by Abu Dhabi Investment Authority (ADIA) and Singapore’s GIC Private Limited. Other investors in the round include China Life Private Equity Investment and Cinda Kunpeng (Shenzhen) Investment Management Co., Ltd.
Taibang was previously known as China Biologic Products Holdings. China Biologic Products was previously listed on Nasdaq and was taken private in April 2021 by a consortium led by Beijing-based Centurium Capital.
China Biologic was considering an initial public offering in Hong Kong in 2022.